Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,654 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,654 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $44.90, for a total value of $74,264.60. Following the sale, the chief executive officer now directly owns 673,064 shares of the company’s stock, valued at $30,220,573.60. This represents a 0.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $49.22 on Friday. The stock has a market capitalization of $2.92 billion, a P/E ratio of -13.67 and a beta of 1.82. The company’s 50-day simple moving average is $45.51 and its 200-day simple moving average is $46.72. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its holdings in shares of Twist Bioscience by 210.2% during the 2nd quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after purchasing an additional 83,287 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after buying an additional 20,035 shares in the last quarter. Barclays PLC raised its stake in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after buying an additional 104,420 shares during the last quarter. FMR LLC boosted its holdings in Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after acquiring an additional 12,327 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after acquiring an additional 21,357 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Scotiabank lifted their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Barclays dropped their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Leerink Partners lifted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird increased their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.